… The Coronavirus Efficacy (COVE) phase 3 trial was launched in late July 2020 to assess
the safety and efficacy of the mRNA-1273 vaccine in preventing SARS-CoV-2 infection. An …

… Here we report the vaccine efficacy and safety results of the final analysis of the blinded
phase of the trial, ending 5.3 months after the second dose, and in additional analyses in …

… The mRNA-1273 vaccine (Moderna) is a lipid nanoparticle … SARS-CoV-2 S glycoprotein
stabilized in the prefusion conformation. The safety, immunogenicity, and efficacy of mRNA-1273 …

… regimen in a large phase 3 trial with a more diverse population to ascertain the safety
and efficacy of the mRNA-1273 vaccine and to assess its level of protection against Covid-19. …

… The 13-month end-of study assessment of this trial and the ongoing phase 3 COVE trial may
provide additional longer-term data on the safety and effectiveness of mRNA-1273 vaccine. …

… SARS-CoV-2 vaccines, such as mRNA-1273, are … efficacy for the current SARS-CoV-2
vaccines. To address this potential risk, modified versions of the prototype mRNA-1273 vaccine …

… mRNA-1273 or modified COVID-19 mRNA vaccines, designed to target emerging SARS-CoV-2
variants as booster vaccines … and waning efficacy for current SARS-CoV-2 vaccines. One …

… of COVID-19, mRNA-1273 vaccination may offer added protection beyond immunity acquired
… -up is needed to fully evaluate VE of mRNA-1273 against emerging SARS-CoV-2 variants. …

… booster dose induced nAb and bAb immune responses that were greater than those
achieved by primary vaccination, regardless of prior SARS-CoV-2 infection. These higher nAb …

… vaccine was safe and well-tolerated. In summary, immunogenicity of mRNA-1273 COVID-19
vaccine … However, it is completely unknown how this translates into vaccine efficacy. A key …